menu_open Columnists
Sheetal Arora

Sheetal Arora

The Economic Times

We use cookies to provide some features and experiences in QOSHE

More information  .  Close

Semaglutide patent expiry: India’s next big public health inflection point

Due to the technical or legal reasons, readability mode is not available for this article. Thank you for your kind understanding.

20.03.2026 10

The Economic Times

Sheetal Arora

Bitter pill, not poison: 100% Trump tariff on imported meds can act as smelling salt for Indian pharma

26.09.2025 10

The Economic Times

Sheetal Arora

Go on, pop the innovation pill: ₹5,000 cr push signals India’s shift from copy to create

23.06.2025 10

The Economic Times

Sheetal Arora

US tariff threat on Indian generics: What it means for pharma

30.03.2025 10

The Economic Times

Sheetal Arora